CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Zootecnia e Engenharia de Alimentos (FZEA) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Currently, I am a Collaborating Researcher at the Laboratory of Comparative and Translational Oncology (LOCT) at FZEA/USP and the Principal Investigator of the Generation Project 2022/06305-7, funded by FAPESP. I hold a degree in Biology from the PUC-Campinas (2010-2013). I completed my Master's in Science in the Animal Bioscience program at FZEA/USP (2014-2016) and a Ph.D. in Science in the Animal Bioscience program at FZEA-USP (2016-2020), under the guidance of Dr. Heidge Fukumasu. My primary focus was on the study of transcription factors associated with the epithelial-mesenchymal transition process in canine breast cancer and epigenetic modulations associated with the self-renewal potential of tumorigenic cells derived from canine and human breast cancer.During my doctoral studies, I conducted research abroad at the Buchmann Institute for Molecular Life Sciences (BMLS, Frankfurt, Germany) under the guidance of Dr. Susanne Müller-Knapp (BEPE/FAPESP). I was awarded the CAPES Thesis Award in 2021 in the field of veterinary medicine for my thesis titled "Exploring Epigenetic Mechanisms to Target Mammary Cancer Cells: A Comparative Approach."In my postdoctoral research, under the supervision of Prof. Dr. Heidge Fukumasu, I worked on the pre-clinical development of a vectorized vaccine for SARS-CoV-2 with the support of CNPq/MCTI (2021/2023). I have a keen interest and experience in molecular and cellular biology, experimental and comparative oncology, epigenetics, and reverse genetics technology for the production of oncolytic viruses. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging types of cancer, largely due to the lack of targetable pathways and the failure of preclinical data to translate into clinical efficacy. To address this, we started an ambitious project to identify new therapeutic targets and develop first steps of an innovative oncolytic virus-based therapy for PDAC, supported by…
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most challenging types of cancer, exhibiting a 5-year survival of only 10%. There is a lack of targetable pathways and a failure of preclinical data to translate into clinical efficacy. We recently started an ambitious project to identify new therapeutic targets and develop first steps of an innovative oncolytic virus-based therapy for…
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most challenging types of cancer exhibiting a lack of targetable pathways. Thus, PDAC has been considered a "graveyard" for drug development. Here we propose an ambitious project which aims to identify new therapeutic targets and develop the first steps of an innovative therapy for PDAC, using relevant models and approaches. For this, …
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignant tumor, with patients showing a low life expectancy on a global scale. This unfavorable scenario is related to multivariable risk factors, nonspecific symptoms, late diagnosis, and, most importantly, the lack of effective therapeutic targets. Three-dimensional organoid models have emerged as an essential tool for stud…
Newcastle disease virus (NDV) has significant potential as a therapeutic approach for the treatment of neoplasms, due to its natural ability to selectively infect and kill cancer cells, as these often have inefficient antiviral systems. With regard to Pancreatic Ductal Adenocarcinoma (PDA), some studies have demonstrated the oncolytic potential of the NDV virus in this type of cancer. In …
3D models that faithfully mimic in vivo tumor biology and improve our understanding of therapeutic responses are challenging but urgent to improve target discovery for PDAC. Cell culture models using tissue-specific ECM components have the ability to maintain transcriptional profiles, cancer stem cell (CSC) properties, and tumorigenicity. In this plan of activity, a Masters' student will …
(Only some records are available in English at this moment)
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most challenging types of cancer exhibiting a lack of targetable pathways. Thus, PDAC has been considered a "graveyard" for drug development. Here we propose an ambitious project which aims to identify new therapeutic targets and develop the first steps of an innovative therapy for PDAC, using relevant models and approaches. For this, …
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most challenging types of cancer exhibiting a lack of targetable pathways. Thus, PDAC has been considered a "graveyard" for drug development. Here we propose an ambitious project which aims to identify new therapeutic targets and develop the first steps of an innovative therapy for PDAC, using relevant models and approaches. For this, …
3D models that faithfully mimic in vivo tumor biology and improve our understanding of therapeutic responses are challenging but urgent to improve target discovery for PDAC. Cell culture models using tissue-specific ECM components have the ability to maintain transcriptional profiles, cancer stem cell (CSC) properties, and tumorigenicity. In this plan of activity, an undergraduate student…
(Only some records are available in English at this moment)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer, with one of the poorest outcomes of all cancer, due to nonspecific symptoms, late diagnosis, and lack of effective therapeutic strategies. Recently, chemical inhibitors have been successfully developed to target KRAS, an important and well-known mutated gene and an oncogenic event of PDAC. Using these inhibitors in a…
Pancreatic Ductal Adenocarcinoma is one of the most aggressive types of cancer, exhibiting significantly low survival rates worldwide. The poor outcomes are related to multifactorial risk factors, nonspecific symptoms, later diagnostic, and lack of therapeutic targets. Three-dimensional organoid models emerge as an essential tool for studying PDAC physiological dynamics in vitro, mimickin…
Mammary tumors are the most frequent type of cancer in female dogs as in women. Besides that, its cells share similar features and can be used to comparative studies and screening of antineoplastic agents. Epigenetic targets are highlighted as potential and innovative therapy against cancer. Both histone deacetylases (HDACs) and bromodomain and extraterminal proteins (BET) inhibitors have…
| 3 / 3 | Ongoing grants |
| 6 / 6 | Ongoing scholarships in Brazil |
| 5 / 5 | Completed scholarships in Brazil |
| 3 / 3 | Completed scholarships abroad |
| 17 / 17 | All research grants and scholarships |
| Associated processes | |